Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 144


Antitumor effects of a monoclonal antibody that binds anionic phospholipids on the surface of tumor blood vessels in mice.

Ran S, He J, Huang X, Soares M, Scothorn D, Thorpe PE.

Clin Cancer Res. 2005 Feb 15;11(4):1551-62.


Increased exposure of anionic phospholipids on the surface of tumor blood vessels.

Ran S, Downes A, Thorpe PE.

Cancer Res. 2002 Nov 1;62(21):6132-40.


Targeting mutant p53 protein and the tumor vasculature: an effective combination therapy for advanced breast tumors.

Liang Y, Besch-Williford C, Benakanakere I, Thorpe PE, Hyder SM.

Breast Cancer Res Treat. 2011 Jan;125(2):407-20. doi: 10.1007/s10549-010-0851-x. Epub 2010 Mar 27.


Plasma protein beta-2-glycoprotein 1 mediates interaction between the anti-tumor monoclonal antibody 3G4 and anionic phospholipids on endothelial cells.

Luster TA, He J, Huang X, Maiti SN, Schroit AJ, de Groot PG, Thorpe PE.

J Biol Chem. 2006 Oct 6;281(40):29863-71. Epub 2006 Aug 10.


Combination of a monoclonal anti-phosphatidylserine antibody with gemcitabine strongly inhibits the growth and metastasis of orthotopic pancreatic tumors in mice.

Beck AW, Luster TA, Miller AF, Holloway SE, Conner CR, Barnett CC, Thorpe PE, Fleming JB, Brekken RA.

Int J Cancer. 2006 May 15;118(10):2639-43.


Inhibition of vascular endothelial growth factor reduces angiogenesis and modulates immune cell infiltration of orthotopic breast cancer xenografts.

Roland CL, Dineen SP, Lynn KD, Sullivan LA, Dellinger MT, Sadegh L, Sullivan JP, Shames DS, Brekken RA.

Mol Cancer Ther. 2009 Jul;8(7):1761-71. doi: 10.1158/1535-7163.MCT-09-0280. Epub 2009 Jun 30.


The proteasome inhibitor bortezomib enhances the activity of docetaxel in orthotopic human pancreatic tumor xenografts.

Nawrocki ST, Sweeney-Gotsch B, Takamori R, McConkey DJ.

Mol Cancer Ther. 2004 Jan;3(1):59-70. Erratum in: Mol Cancer Ther. 2009 Feb;8(2):479.


Effects of the combination of RAD001 and docetaxel on breast cancer stem cells.

Zhang X, Zhang S, Liu Y, Liu J, Ma Y, Zhu Y, Zhang J.

Eur J Cancer. 2012 Jul;48(10):1581-92. doi: 10.1016/j.ejca.2012.02.053. Epub 2012 Mar 13.


Targeted anti-vascular endothelial growth factor receptor-2 therapy leads to short-term and long-term impairment of vascular function and increase in tumor hypoxia.

Franco M, Man S, Chen L, Emmenegger U, Shaked Y, Cheung AM, Brown AS, Hicklin DJ, Foster FS, Kerbel RS.

Cancer Res. 2006 Apr 1;66(7):3639-48.


Novel anti-denatured collagen humanized antibody D93 inhibits angiogenesis and tumor growth: An extracellular matrix-based therapeutic approach.

Pernasetti F, Nickel J, Clark D, Baeuerle PA, Van Epps D, Freimark B.

Int J Oncol. 2006 Dec;29(6):1371-9.


Inactivation of NF-kappaB by 3,3'-diindolylmethane contributes to increased apoptosis induced by chemotherapeutic agent in breast cancer cells.

Rahman KM, Ali S, Aboukameel A, Sarkar SH, Wang Z, Philip PA, Sakr WA, Raz A.

Mol Cancer Ther. 2007 Oct;6(10):2757-65. Epub 2007 Oct 3.


Inhibition of metastasis, angiogenesis, and tumor growth by Chinese herbal cocktail Tien-Hsien Liquid.

Chia JS, Du JL, Hsu WB, Sun A, Chiang CP, Wang WB.

BMC Cancer. 2010 Apr 30;10:175. doi: 10.1186/1471-2407-10-175.


YM155, a novel survivin suppressant, enhances taxane-induced apoptosis and tumor regression in a human Calu 6 lung cancer xenograft model.

Nakahara T, Yamanaka K, Hatakeyama S, Kita A, Takeuchi M, Kinoyama I, Matsuhisa A, Nakano K, Shishido T, Koutoku H, Sasamata M.

Anticancer Drugs. 2011 Jun;22(5):454-62. doi: 10.1097/CAD.0b013e328344ac68.


Nontoxic suramin treatments enhance docetaxel activity in chemotherapy-pretreated non-small cell lung xenograft tumors.

Lu Z, Wientjes TS, Au JL.

Pharm Res. 2005 Jul;22(7):1069-78. Epub 2005 Jul 22.

Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk